Vitamin D and UV: Risks and Benefits


Key Points

  • Vitamin D is important in bone metabolism.

  • Studies have suggested that vitamin D may lower the risk of developing certain cancers and provide benefit in several diseases, although a causal relationship has yet to be established through clinical trials.

  • Adequate vitamin D levels can be maintained with oral supplementation.

  • Because of known side effects of unprotected exposure to natural and artificial UV radiation, using UV exposure as a means of obtaining adequate serum vitamin D levels should be discouraged.

History

Vitamin D is a fat-soluble prohormone that plays an important role in calcium and phosphorus homeostasis as well as in many organ systems throughout the body. There are two major physiologically relevant forms of vitamin D: D 2 (ergocalciferol) and D 3 (cholecalciferol). Vitamin D 2 , which is present in yeast and mushrooms, is derived from ergosterol, a yeast and plant sterol. Vitamin D 3 is produced photochemically in the skin from 7-dehydrocholesterol, a cholesterol precursor.

The modern history of vitamin D began in the mid-1800s, when it was noticed that city children were more likely to have rickets than rural children. Half a century later, Palm reported that children raised in sunny climates virtually never developed rickets. McCollum isolated vitamin D, and Windaus its precursors, receiving the Nobel Prize.

Sources and metabolism of vitamin D

In humans, vitamin D is obtained naturally through two sources, diet and sunlight. Very few foods inherently contain significant amounts of vitamin D. Fatty fish like salmon, tuna, and mackerel, as well as fish liver oils are among the best sources, providing 200 to 1600 IU per serving. Beef liver, cheese, and egg yolks provide small amounts of vitamin D – 12 to 20 IU per serving – and some mushrooms contain variable amounts. The majority of dietary vitamin D in countries like the United States and Canada comes from foods such as milk, milk products, juices, and cereal products that are fortified with vitamin D. One 8 ounce serving of fortified milk or orange juice in the United States provides approximately 100 IU of vitamin D ( Table 60.1 ).

Table 60.1
Common Food Sources of Vitamin D
Source: .
Food International Units (IU) per Serving
Atlantic herring, 3.5 ounces 1600
Cod liver oil, 1 tablespoon 1360
Mushrooms, enriched with vitamin D, 3 ounces 400
Salmon, 3.5 ounces 360
Mackerel, 3.5 ounces 345
Sardines, canned in oil, drained, 1.75 ounces 250
Tuna fish, canned in oil, 3 ounces 200
Orange juice fortified with vitamin D, 1 cup (amount of added vitamin D varies) 142
Milk, non-fat, reduced fat, and whole, vitamin D fortified, 1 cup 98
Margarine, fortified, 1 tablespoon 60
Ready-to-eat cereal, fortified, 0.75–1 cup (amount of added vitamin D varies) 40
Egg, 1 whole (vitamin D is found in yolk) 20
Liver, beef, 3.5 ounces 15
Cheese, Swiss, 1 ounce 12

The major natural source of vitamin D in humans is from the exposure of skin to sunlight. UVB radiation is absorbed by cutaneous 7-dehydrocholesterol to form pre-vitamin D 3 ( Fig. 60.1 ). This process largely occurs in the stratum basale and stratum spinosum, where 7-dehydrocholesterol is the most concentrated. Pre-vitamin D 3 undergoes a temperature-dependent isomerization to form vitamin D 3 , which is then hydroxylated by the liver to 25-hydroxyvitamin D [25(OH)D] via the 25-hydroxylase enzyme. An additional hydroxylation by the kidney via the 1α-hydroxylase enzyme is necessary to produce the physiologically active vitamin D metabolite, 1α,25-dihydroxyvitamin D [1,25(OH) 2 D], which is best known for promoting intestinal absorption of calcium and phosphorus, decreasing their clearance from the kidney, and promoting bone mineralization.

Figure 60.1, Synthesis of and metabolism of vitamin D. Cutaneous 7-dehydrocholesterol absorbs UVB radiation to form pre-vitamin D 3 , which then becomes vitamin D 3 . Vitamin D 3 and vitamin D 2 are also obtained from the diet. Vitamin D undergoes sequential hydroxylation by enzymes in the liver and kidney to become the physiologically active metabolite, 1α,25-dihydroxyvitamin D.

In addition to foods and sunlight, vitamin D is also available in supplement form as D 2 or D 3 . Comparisons between the two forms have shown D 2 to have a shorter shelf-life, diminished binding of its metabolites to vitamin D binding protein in plasma, and less efficacy in raising and maintaining serum vitamin D metabolite levels. Given these findings, vitamin D 3 is preferred to D 2 for supplementation.

Minimal winter sunlight exposure reaches the lower epidermal layers, and therefore little vitamin D is produced in the wintertime. Melanin, which is produced by melanocytes located in the stratum basale, also affects the quantity of vitamin D produced by absorbing UVB. Melanin concentration determines the amount of UVB that can interact with the 7-dehydrocholesterol in the lower epidermal layers, though it does not change the capacity to produce vitamin D; individuals with darker skin pigmentation may need three to six times longer exposure to produce the same amount of pre-vitamin D as those with fair skin. Skin from older individuals contains less substrate for pre-vitamin D synthesis, and they may produce up to four times less pre-vitamin D than their younger counterparts.

Vitamin D in health and disease

Though 25(OH)D has low biological activity, its serum concentration, which can be measured in commercial laboratories, is the most widely used biomarker for an individual's vitamin D status. 25(OH)D levels have been correlated with important health endpoints ( Table 60.2 ); the levels are commonly reported as either nmol/L or ng/mL ( Table 60.3 ). One complication in determining vitamin D status is that there is variability among the laboratories that conduct the analyses as well as in the various available assays. However, a new standard reference material for 25(OH)D became available in July 2009, which should allow for more standardization across laboratories.

Table 60.2
Summary of Epidemiologic Associations Between Vitamin D and Health and Disease
Measurement and Outcome Study: Findings [reference]
Serum 25(OH)D and rickets in children Meta-analysis: Low 25(OH)D levels associated with established rickets [8]
Serum 25(OH)D and hip bone mineral density NHANES III: Positive association [9]
Supplemental vitamin D and non-vertebral fractures Meta-analysis: Doses below 400 IU/day did not decrease risk (RR 1.02, 95% CI 0.92–1.15); doses above 480 IU/day decreased risk (RR 0.80, 95% CI 0.72–0.89) [10]
Supplemental vitamin D and hip fractures Meta-analysis: Doses below 400 IU/day did not decrease risk (RR 1.09, 95% CI 0.90–1.32); doses above 480 IU/day decreased risk (RR 0.82, 95% CI 0.69–0.97) [10]
Serum 25(OH)D and lower extremity function NHANES III: Highest 25(OH)D quintile vs. lowest: faster 8-foot walk test ( p < 0.001) and faster sit-to-stand test ( p = 0.017) [11]
Supplemental vitamin D and falls Meta-analysis: Decreased risk with supplementation (OR 0.78, 95% CI 0.64–0.92) [12]
Serum 25(OH)D and colorectal cancer (CRC) NHS: Inverse association * ( p = 0.02); OR 0.53 for highest 25(OH)D quintile (95% CI 0.27–1.04) [13]
WHI: Inverse association; OR 2.53 for lowest 25(OH)D quintile (95% CI 1.49–4.32) [14]
EPIC: Inverse association; OR 1.28 for lowest 25(OH)D quartile (95% CI 1.05–1.56) [15]
NHANES III: Inverse association for mortality from CRC; RR 0.28 for highest 25(OH)D tertile (95% CI 0.11–0.68) [16]
Serum 25(OH)D and prostate cancer PHS: Increased risk of aggressive cancer for low 25(OH)D (OR 2.1, 95% CI 1.2–3.4) [17]
HPFS: No association ( p = 0.20) [18]
PLCO: No association ( p trend = 0.05), though higher 25(OH)D may be associated with increased risk of aggressive cancer [19]
Serum 25(OH)D and breast cancer NHANES III: Decreased risk of mortality from breast cancer for high 25(OH)D (HR 0.28, 95% CI 0.08–0.93) [16]
Meta-analysis: Inverse association ( p trend < 0.001). OR 0.50 for highest 25(OH)D quintile [20]
Case-control: Inverse association ( p trend < 0.0001). OR 0.31 for highest 25(OH)D quintile (95% CI 0.24–0.42) [21]
Serum 25(OH)D and pancreatic cancer HPFS: Inverse association. RR 0.49 for higher 25(OH)D (95% CI 0.28–0.86) [22]
ATBC: Positive association. OR 2.92 for highest 25(OH)D quintile (95% CI 1.56–5.48) [23]
Total vitamin D intake and pancreatic cancer Meta-analysis: Decreased risk for >600 IU/day vs. <150 IU/day (RR 0.59, 95% CI 0.40–0.88) [24]
Serum 25(OH)D and non-Hodgkin lymphoma (NHL) ATBC: Inverse association for cases diagnosed less than 7 years from baseline ( p trend = 0.01). OR 0.43 for highest vs. lowest 25(OH)D tertile (95% CI 0.23–0.83) [25]
HPFS: No association [22]
NHANES III: No association for mortality from NHL [16]
Serum 25(OH)D and lung cancer Case-control: Positive association for recurrence-free survival in early-stage non-small cell lung cancer patients ( p trend = 0.002). AHR 0.45 for highest 25(OH)D quartile (95% CI 0.24–0.82) [26]
Case-control: No association for recurrence-free survival in advanced-stage non-small cell lung cancer patients [27]
NHANES III: No association for mortality from lung cancer [16]
HPFS: No association [22]
Cohort: No association overall, but inverse association for women (RR 0.16, 95% CI 0.04–0.59, p trend <0.001) and younger participants (RR 0.34, 95% CI 0.13–0.90, p trend = 0.04) [28]
Serum 25(OH)D and total cancer HPFS: Inverse association. RR 0.83 per increase of 25 nmol/L in predicted 25(OH)D (95% CI 0.74–0.92). Inverse association for total cancer mortality. RR 0.71 per increase of 25 nmol/L in predicted 25(OH)D level (95% CI 0.60–0.83) [22]
Cohort: Inverse association for total cancer mortality. HR 0.66 per increase of 25 nmol/L in 25(OH)D (95% CI 0.49–0.89) [29]
NHANES III: No association for total cancer mortality [16]
Supplemental vitamin D and total cancer RCT: No association [30]
RCT: No association [31]
Serum 25(OH)D and cardiovascular health NHANES III: Inverse association for cardiac risk factors. For lowest 25(OH)D quartile vs. highest, OR 1.30 for hypertension, OR 1.98 for diabetes mellitus, OR 2.29 for obesity, and OR 1.47 for high serum triglyceride levels ( p < 0.001 for all) [32]. Low 25(OH)D levels had increased self-reported angina, myocardial infarction, and heart failure (OR 1.20, 95% CI 1.01–1.36) [33]
Cohort: Inverse association for metabolic syndrome. Inverse association for high hemoglobin A1C, hypertension, and hypertriglyceridemia ( p < 0.004 for all) [34]
NHS: Inverse association for incident hypertension. RR 2.67 for low 25(OH)D (95% CI 1.05–6.79) [35]
HPFS: Inverse association for incident hypertension. RR 6.13 for low 25(OH)D (95% CI 1.00–37.8) [35]
Cohort: Inverse association for cardiovascular-related death. For low 25(OH)D, HR 2.84 for death due to heart failure (95% CI 1.20–6.74), HR 5.05 for sudden cardiac death (95% CI 2.13–11.97) [36]
Cohort: Inverse association for cardiovascular-related death. HR 0.76 for highest 25(OH)D quintile (95% CI 0.60–0.95) [37]
Supplemental vitamin D and blood pressure RCT: 800 IU/day with 1200 mg/day of calcium decreased SBP by 13 mmHg and heart rate by 4 bpm compared to calcium alone ( p = 0.02) [38]
Review: Studies in Denmark, Taiwan, the UK, and the WHI Study in the US showed no association, though lower doses (∼︀400 IU) of vitamin D were used [39]
UVB exposure and blood pressure RCT: UVB exposure decreased both SBP and DBP by 6 mmHg ( p < 0.001) [40]
Serum 25(OH)D and all-cause mortality NHANES III: Inverse association. HR 0.95 per increase of 10 nmol/L in serum 25(OH)D (95% CI 0.92–0.98). AHR 1.83 for lowest 25(OH)D quintile (95% CI 1.14–2.94), AHR 1.47 for second lowest quintile (95% CI 1.09–1.97) [41]
Cohort: Inverse association. HR 2.08 for lower two 25(OH)D quartiles (95% CI 1.60–2.70) [42]
Supplemental vitamin D and all-cause mortality Meta-analysis: Adjusted mean daily dose of 528 IU associated with decreased mortality (RR 0.93, 95% CI 0.87–0.99) [43]
25(OH)D, 25-hydroxyvitamin D; AHR, adjusted hazard ratio; ATBC, Alpha-Tocopherol, Beta-Carotene Trial; CI, confidence interval; DBP: diastolic blood pressure; EPIC, European Prospective Investigation into Cancer and Nutrition; HPFS, Health Professionals Follow-Up Study; HR, hazard ratio; NHANES III, Third National Health and Nutritional Examination Survey; NHS, Nurses' Health Study; OR, odds ratio; PHS, Physicians' Health Study; PLCO, Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial; RCT, randomized controlled trial; RR, relative risk; SBP, systolic blood pressure; WHI, Women's Health Initiative.

* Inverse association: higher 25(OH)D levels were associated with lower risk.

Table 60.3
Equivalent Values of Serum 25(OH)D Levels Expressed in Two Different Units
nmol/L ng/mL
30 12
50 20
75 30
To convert nmol/L to ng/mL, divide by 2.496.

You're Reading a Preview

Become a Clinical Tree membership for Full access and enjoy Unlimited articles

Become membership

If you are a member. Log in here